Urothelial carcinoma presenting with painless hematuria; strongly linked to smoking.
Also known as: bladder cancer, urothelial carcinoma, transitional cell carcinoma, TCC
Overview
Malignancy arising from the urothelium lining the bladder. Urothelial carcinoma (formerly transitional cell carcinoma) accounts for >90% of cases in developed countries. Categorized as non-muscle-invasive bladder cancer (NMIBC; Ta, T1, Tis) — 75% at diagnosis — or muscle-invasive bladder cancer (MIBC; T2+).
Epidemiology
~83,000 new cases and ~17,000 deaths annually in the US. Fourth most common cancer in men. Male:female ratio ~3:1. Median age at diagnosis 73 years. Most cases occur in current or former smokers.
Try two board-style Bladder Cancer questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1RenalMedium
A 68-year-old man presents after a single episode of painless gross hematuria. He denies dysuria, flank pain, fever, or trauma and takes no anticoagulants. Vital signs are normal and the physical examination is unremarkable. Urinalysis shows more than 100 red blood cells per high-power field with no casts, no proteinuria, no pyuria, and negative nitrites. Cystoscopy and CT urography are planned. Which of the following is the strongest risk factor for the suspected diagnosis?
ASaccharin consumption
BFrequent NSAID use
CCoffee consumption
DRecurrent cystitis
ECigarette smoking
Reveal answer & full explanation
Correct answer: E — Cigarette smoking
ASaccharin consumption
BFrequent NSAID use
CCoffee consumption
DRecurrent cystitis
ECigarette smoking✓
Why Cigarette smoking is correct
Painless gross hematuria in an older adult with no infection, casts, or proteinuria is urothelial (bladder) carcinoma until proven otherwise, prompting cystoscopy and CT urography.
Cigarette smoking is the single strongest and most prevalent modifiable risk factor, accounting for roughly half of all urothelial bladder cancers through excreted aromatic-amine and polycyclic-hydrocarbon carcinogens.
Risk is dose-dependent and declines but does not normalize after cessation.
Why the others are wrong
Coffee consumption — Any epidemiologic association is weak and largely confounded by smoking; it is not an established strong risk factor (weak-association trap).
Recurrent cystitis — Chronic bladder inflammation predisposes mainly to squamous cell carcinoma and is a far weaker contributor than smoking to the urothelial cancer suspected here (confused-with-subtype trap).
Frequent NSAID use — Historic phenacetin-containing analgesics were linked to urothelial cancer, but routine modern NSAID use is not a strong risk factor (anchoring on an outdated analgesic association).
Saccharin consumption — saccharin caused bladder tumors in rats in the 1970s and once carried a US warning label, but the mechanism is specific to rat urine chemistry and human studies have not shown a meaningful increase in risk; it was removed from the federal carcinogen list in 2000 (outdated-animal-data trap).
Question 2RenalEasy
A 35-year-old man presents with painless total hematuria without clots. He smokes and works in a rubber manufacturing plant. Urinalysis confirms RBCs with no casts. Urine cytology shows atypical cells. Which is the most likely diagnosis?
AIgA nephropathy
BHemorrhagic cystitis
CBladder cancer
DRenal cell carcinoma
ERenal papillary necrosis
Reveal answer & full explanation
Correct answer: C — Bladder cancer
AIgA nephropathy
BHemorrhagic cystitis
CBladder cancer✓
DRenal cell carcinoma
ERenal papillary necrosis
Why Bladder cancer is correct
Painless hematuria in a smoker with occupational chemical exposure (aniline dyes, rubber manufacturing, aromatic amines) is bladder cancer until proven otherwise
Renal cell carcinoma — also causes painless hematuria and is linked to smoking, but it arises from renal tubular epithelium and rarely sheds cells into the urine, so cytology is usually negative, and the aromatic amine exposure of rubber manufacturing is a risk factor for urothelial rather than renal cell carcinoma
Renal papillary necrosis — can cause hematuria, often with flank pain or colic from sloughed papillae, but it occurs in the setting of analgesic overuse, sickle cell disease or trait, diabetes, or pyelonephritis with obstruction, none of which is reported here, and it would not explain atypical cells on cytology
Hemorrhagic cystitis — diffuse bladder mucosal bleeding from cyclophosphamide or ifosfamide (acrolein), pelvic radiation, or viral infection (BK virus, adenovirus) typically causes dysuria, urgency, suprapubic pain, and often clots; this patient has painless hematuria without clots and no such exposure is described
IgA nephropathy — the most common primary glomerulonephritis, it often presents in young men as painless gross hematuria during or shortly after an upper respiratory infection, but glomerular bleeding typically produces dysmorphic RBCs, often with RBC casts or proteinuria, and the atypical cytology and occupational exposure point to urothelial cancer instead
Additional high-yield points
Risk factors for bladder cancer: smoking (strongest risk factor), chemical exposures (aniline dyes, rubber manufacturing, aromatic amines), cyclophosphamide, and schistosomiasis
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Bladder Cancer outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Carcinogens are concentrated in urine and have prolonged contact with the urothelium. Mutations accumulate in oncogenes (FGFR3 — papillary low-grade tumors) and tumor suppressors (TP53, RB1 — high-grade and muscle-invasive). Field cancerization explains multifocal and recurrent disease throughout the urothelium (ureters, renal pelvis, urethra). NMIBC tumors are slow-growing and recurrent but rarely metastasize; MIBC has rapid progression and metastatic potential.
Clinical presentation
Symptoms
Painless gross hematuria — most common presenting symptom (~80%); intermittent
Microscopic hematuria (often detected on routine UA)
Irritative voiding symptoms — dysuria, frequency, urgency (more common with CIS)
Definitive diagnosis requires cystoscopic biopsy with histologic confirmation. Transurethral resection of bladder tumor (TURBT) provides both diagnosis and initial treatment, with muscularis propria sampling required to stage T category.
Labs
Urinalysis with microscopy — confirms hematuria; rule out infection (urine culture)
Urine cytology — useful for high-grade tumors and CIS; low sensitivity for low-grade (~40%)
Urine tumor markers (NMP22, BTA) — adjunct, not replacement for cystoscopy
BMP, CBC, LFTs
Imaging
Cystoscopy — gold standard diagnostic procedure; allows direct visualization and biopsy
CT urography with multi-phase imaging — evaluates upper tract (5% of urothelial cancers involve renal pelvis/ureters)
MR urography — alternative if contrast contraindicated
MRI pelvis for staging muscle invasion
CT chest/abdomen/pelvis for staging in MIBC
Bone scan or PET if metastasis suspected
Diagnostic algorithm
Stage
Description
Standard Treatment
Ta
Non-invasive papillary, low or high grade
TURBT ± intravesical therapy
Tis (CIS)
Flat, high-grade in situ
TURBT + intravesical BCG
T1
Invades lamina propria
TURBT + BCG (or cystectomy if high-risk)
T2
Invades muscularis propria
Neoadjuvant cisplatin-based chemo (if eligible) → radical cystectomy; or trimodality therapy in selected patients
T3
Invades perivesical tissue
Radical cystectomy + neoadjuvant chemo
T4
Invades adjacent organs
Chemo + cystectomy or chemoradiation
N+/M+
Lymph node or distant metastasis
Systemic therapy (chemo + immunotherapy)
Bladder cancer staging (TNM) and standard treatment approach by stage.
Treatment
First-line
Non-muscle invasive bladder cancer (NMIBC; Ta, T1, Tis):
Transurethral resection of bladder tumor (TURBT) — complete excision with muscularis propria sample
Single intravesical chemotherapy (mitomycin C or gemcitabine) within 24 hours of TURBT for suspected or known low- or intermediate-risk disease — reduces recurrence
Intravesical BCG (Bacillus Calmette-Guérin) induction + maintenance — for high-risk NMIBC (for example high-grade T1, CIS, or recurrent high-grade Ta)
Surveillance cystoscopy every 3 months × 2 years, then every 6 months × 2 years, then annually
Muscle-invasive bladder cancer (MIBC; T2+):
Radical cystectomy with bilateral pelvic lymph node dissection + urinary diversion (ileal conduit or neobladder)
Neoadjuvant cisplatin-based chemotherapy (e.g., dose-dense MVAC or gemcitabine/cisplatin) — improves overall survival, given before cystectomy
Bladder-sparing tri-modality therapy — maximal TURBT + chemoradiation — for selected patients (small tumor, no CIS, good function)
Alternative first-line: platinum-based chemotherapy (gemcitabine + cisplatin, or carboplatin if cisplatin-ineligible) followed by avelumab maintenance if no progression; gemcitabine-cisplatin + nivolumab is another option
Pembrolizumab (checkpoint inhibitor) for progression after platinum chemotherapy
Second-line / adjunct
BCG-unresponsive NMIBC: pembrolizumab, nadofaragene firadenovec, or radical cystectomy
Painless gross hematuria in an adult >35-40 years requires evaluation with cystoscopy and upper tract imaging — even if it resolves.
Smoking is the single greatest risk factor; counsel cessation as part of treatment (improves outcomes).
BCG is a live attenuated tuberculosis vaccine that activates local immune response; works for high-risk NMIBC and CIS but not muscle-invasive disease.
Schistosoma haematobium causes squamous cell bladder cancer in endemic areas (Egypt, Sub-Saharan Africa).
Field cancerization: urothelial carcinoma can arise anywhere in the urothelium — always evaluate upper tract (renal pelvis, ureters) in addition to bladder.
Microhematuria (≥3 RBC/HPF) per AUA/SUFU (2020, amended 2025) is risk-stratified: low risk → repeat UA within 6 months (or cystoscopy + renal US by shared decision); intermediate risk → cystoscopy + renal ultrasound; high risk (e.g., men ≥60, >30 pack-years, >25 RBC/HPF, prior gross hematuria) → cystoscopy + CT urography. Age ≥60 is only an intermediate-risk criterion in women (other features can still make a woman high risk), and the tiers guide the evaluation; they do not diagnose bladder cancer. Gross hematuria → cystoscopy + CT urography.
References
AUA/SUO 2026 — 2026 Updates to the Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline (Clark et al., J Urol 2026)
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.